Novel HDAC inhibitors, including SL142, SL325, HTPB, and CG0006, demonstrate greater degree of apoptosis of NSCLC cells through induction of caspase-3 activity, disruption of F-actin dynamics, inhibition of mitochondrial membrane potential 2 (MMP2) and MMP9, and increased p21 and p27 expression (Hwang et al., 2009; Han et al., 2010; Shieh et al., 2012). This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.